Skip to main content Accessibility help
×
Hostname: page-component-77c89778f8-gq7q9 Total loading time: 0 Render date: 2024-07-19T07:41:38.352Z Has data issue: false hasContentIssue false

32 - Disseminated Mycobacterium avium complex infection

Published online by Cambridge University Press:  23 December 2009

Robert N. Husson
Affiliation:
Children's Hospital, Division of Infectious Diseases, Boston, MA
Steven L. Zeichner
Affiliation:
National Cancer Institute, Bethesda, Maryland
Jennifer S. Read
Affiliation:
National Institutes of Health, Bethesda, Maryland
Get access

Summary

Non-tuberculous mycobacteria are major opportunistic pathogens of HIV-infected children and adults who have severe immunosuppression. Organisms of the Mycobacterium avium complex are the predominant pathogens, typically causing systemic infection, (referred to as disseminated M. avium complex infection or DMAC). With the advent of highly active antiretroviral therapy (HAART) and the resulting improved preservation of immune competence, DMAC infection has become less common [1]. Among HIV-infected children with advanced disease, however, DMAC infection remains an important cause of morbidity and mortality, so that prevention and management of non-tuberculous mycobacterial infection are important aspects of the care of children with AIDS.

Epidemiology

Mycobacterium avium and many of the other non-tuberculous mycobacteria are widely distributed in the environment. They are found in water and soil in nature and have been identified in food and in institutional water systems [2, 3]. These organisms are uncommon causes of infection in normal hosts, and thus are opportunistic pathogens in patients with depressed cell-mediated immunity, including those with HIV infection.

While DMAC infection is a major opportunistic infection in North America and Western Europe, it is uncommonly identified in persons with AIDS in Africa or other less-developed areas of the world. It is not known whether this difference reflects differences in distribution of pathogenic strains of MAC in the environment. Almost certainly, part of this difference is the result of lack of blood culture testing to identify DMAC infection in these settings.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Palella, F. J. Jr., Delaney, K. M., Moorman, A. C.et al.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. human immunodeficiency virus Outpatient Study Investigators. N. Engl. J. Med. 1998;338(13):853–860.CrossRefGoogle ScholarPubMed
Reyn, C. F., Waddell, R. D., Eaton, T.et al.Isolation of Mycobacterium avium complex from water in the United States, Finland, Zaire, and Kenya. J. Clin. Microbiol. 1993;31(12):3227–3230.Google Scholar
Reyn, C., Maslow, J., Barber, T., Falkinham, J. III, Arbeit, R.Persistent colonisation of potable water as a source of Mycobacterium avium infection in acquired immune deficiency syndrome. Lancet 1994;343:1137–1141.CrossRefGoogle Scholar
Pettipher, C. A., Karstaedt, A. S., Hopley, M.Prevalence and clinical manifestations of disseminated Mycobacterium avium complex infection in South Africans with acquired immunodeficiency syndrome. Clin. Infect. Dis. 2001;33(12):2068–2071.CrossRefGoogle ScholarPubMed
Inderlied, C., Kemper, C., Bermudez, L.The Mycobacterium avium complex. Clin. Microbiol. Rev. 1993;6:266–310.CrossRefGoogle ScholarPubMed
Woods, G. L.Susceptibility testing for mycobacteria. Clin. Infect. Dis. 2000;31(5):1209–1215.Google ScholarPubMed
Dankner, W. M., Lindsey, J. C., Levin, M. J.Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr. Infect. Dis. J. 2001;20(1):40–48.CrossRefGoogle ScholarPubMed
United States Public Health Service/IDSA Prevention of Opportunistic Infections Working Group. 2001 United States Public Health Service/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human ImmunodeficiencyVirus 2001:1–65.
Hoyt, L., Oleske, J., Holland, B., Connor, E.Nontuberculous mycobacteria in children with acquired immunodeficiency syndrome. Pediatr. Infect. Dis. J. 1992;11:354–360.CrossRefGoogle ScholarPubMed
Lewis, L., Butler, K., Husson, R.et al.Defining the population of human immunodeficiency virus-infected children at risk for Mycobacterium avium-intracellulare. J. Pediatr. 1992;121:677–683.CrossRefGoogle ScholarPubMed
Gordin, F., Cohn, D., Sullam, P., Schoenfelder, J., Wynne, P., Horsburgh, C. J.Early manifestations of disseminated Mycobacterium avium complex disease: a prospective evaluation. J. Infect. Dis. 1997;176:126–132.CrossRefGoogle ScholarPubMed
Hafner, R., Inderlied, C. B., Peterson, D. M.et al.Correlation of quantitative bone marrow and blood cultures in acquired immune deficiency syndrome patients with disseminated Mycobacterium avium complex infection. J. Infect. Dis. 1999;180(2):438–447.CrossRefGoogle Scholar
Kaplan, J. E., Hanson, D., Dworkin, M. S.et al.Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 2000;30 Suppl. 1:S5–S14.CrossRefGoogle ScholarPubMed
Kaplan, J. E., Hanson, D. L., Jones, J. L., Dworkin, M. S.Viral load as an independent risk factor for opportunistic infections in human immunodeficiency virus-infected adults and adolescents. acquired immune deficiency syndrome 2001;15(14):1831–1836.Google Scholar
Horsburgh, C. Jr., Havlik, J., Ellis, D.et al.Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am. Rev. Respir. Dis. 1991;144:557–559.CrossRefGoogle ScholarPubMed
Husson, R., Ross, L., Inderlied, C.et al.Orally administered clarithromycin for the treatment of systemic Mycobacterium avium complex infection in children with acquired immunodeficiency syndrome. J. Pediatr. 1994;124:807–814.CrossRefGoogle ScholarPubMed
Shafran, S. D., Singer, J., Zarowny, D. P.et al.A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in acquired immune deficiency syndrome: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazamine and ciprofloxacin. N. Engl. J. Med. 1996;335:377–383.CrossRefGoogle Scholar
Dube, M., Sattler, F., Torriani, F.et al.A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. J. Infect. Dis. 1997;176:1225–1232.CrossRefGoogle ScholarPubMed
Ward, T. T., Rimland, D., Kauffman, C., Huycke, M., Evans, T. G., Heifets, L.Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs human immunodeficiency virus Research Consortium. Clin. Infect. Dis. 1998;27(5):1278–1285.CrossRefGoogle ScholarPubMed
Dunne, M., Fessel, J., Kumar, P.et al.A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin. Infect. Dis. 2000;31(5):1245–1252.CrossRefGoogle ScholarPubMed
Gordin, F. M., Sullam, P. M., Shafran, S. D.et al.A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin. Infect. Dis. 1999;28(5):1080–1085.CrossRefGoogle ScholarPubMed
Chaisson, R. E., Keiser, P., Pierce, M.et al.Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with human immunodeficiency virus infection. acquired immune deficiency syndrome 1997;11(3):311–317.Google ScholarPubMed
Piscitelli, S., Flexner, C., Minor, J., Polis, M., Masur, H.Drug interactions in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 1996;23:685–691.CrossRefGoogle ScholarPubMed
Tseng, A., Foisy, M.Management of drug interactions in patients with human immunodeficiency virus. Ann. Pharmacother. 1997;31:1040–1058.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×